Drug Channels
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/

Drug Channels's articles

  1. Department: HBC

As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact

Today’s guest post comes from Lara Loveman, VP of Pharma Solutions at Outcomes. Lara discusses how shifting market forces and evolving reimbursement models are reshaping pharmaceutical marketing strategies. She suggests that pharmacist-led interventions—particularly in chronic disease management—can both protect pharmaceutical investment and drive better health outcomes. Click here to learn about Outcomes’ pharmacist-led interventions solution. […]
2 min read
0
  1. Department: HBC

Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble

On Monday, Cigna announced that it would be abandoning traditional manufacturer rebates and moving to a new, “rebate-free” approach—essentially a point-of-sale (POS) rebate model paired with a cost-plus pharmacy reimbursement framework. Here’s the press release. Moving manufacturers’ rebates and discounts to the point of dispensing is a big win for patients, who can share in […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting

Eeek! It’s time for the Drug Channels Halloween roundup of terrifying tales from the dark corners of the healthcare system. Gather your favorite demon hunters and help maintain the Honmoon. This month’s tricks and treats include: Vampiric! How vertically integrated insurers can drain the lifeblood from the U.S. healthcare system Boo! Chilling stories of the shady […]
2 min read
0
  1. Data & Insights

Let’s Be DIRECT: We Have an Access and Affordability Problem to Solve

Today’s guest post comes from Mark Thierer, Chief Executive Officer of EVERSANA. Mark explains how combining direct-to-patient and direct-to-payer strategies can improve transparency, streamline access, and better align key stakeholders. He introduces EVERSANA DIRECT, the company’s new approach to market access. To learn more, visit eversana.com/DIRECT. Read on for Mark’s insights. Read more » © […]
2 min read
0
  1. Trends & External Forces

The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices

Vertical integration continues to reshape U.S. healthcare, as detailed in DCI’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Our latest analysis shows how the Big Three companies—Cencora, Cardinal Health, and McKesson—are extending their reach far beyond drug distribution, building influence throughout the drug channel. In recent years, these companies have spent more […]
2 min read
0
  1. Data & Insights

Informa Connect’s Trade and Channel Strategies

Informa Connect’s Trade and Channel Strategies December 9-11, 2025 | W Philadelphia Exclusive Offer—Use promo 25DC10 to save 10%* The stakes have never been higher. With seismic shifts in distribution models, health policy and market access strategies, falling behind on critical trends could mean losing your competitive edge. If you’re a trade, channel, market access […]
3 min read
0
  1. Data & Insights

Why Site of Care Is the Hidden Barrier in Neurology’s Bright Pipeline

Today’s guest post comes from from Chad Zerangue, Founder of InfuseFlow and Senior Director, Enterprise Provider Sales at CareMetx. Chad explains how barriers to access for infused therapies—including site-of-care changes and financial clearance delays—often cause patients to disengage before receiving the first dose. He shares one patient’s story illustrating the need for a strong patient […]
2 min read
0
  1. Data & Insights

NOW AVAILABLE: The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

I am pleased to announce Drug Channels Institute’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download. Download a free 25-page report overview—including key industry trends, “What’s New,” Table of Contents, and List of Exhibits Review pricing/license options and download the full 2025-26 report Special launch pricing is […]
3 min read
0
  1. Data & Insights

Direct-to-Patient 2.0: Why Today’s DTP Programs Can’t Scale—and What Pharma Must Do Next

Today’s guest post comes from Deepak Thomas, Founder and CEO of PHIL. Deepak explores how demographic shifts and digital expectations are reshaping patient engagement. He argues that to stay competitive, pharmaceutical manufacturers must adopt integrated direct-to-patient (DTP) platforms that streamline access, support insurance coverage, and deliver sustainable commercial impact. Click here to learn more about […]
2 min read
0
  1. Department: HBC

The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2025. The 340B Drug Pricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). Drug […]
2 min read
0
  1. Trends & External Forces

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from July 2025. It’s time for Drug Channels’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. This year’s review includes the […]
3 min read
0
  1. Owned Brands (Private Label)

The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from July 2025. ICYMI, Express Scripts will boot the reference products from its 2026 formulary, but will cling to its biosimilar pricing double standard. […]
2 min read
0
Post Views: 37,744